Abbott Laboratories (ABT.US) faces increased scrutiny after Daiwa downgraded its stock to 'Neutral' from 'Outperform' and revised the price target from $113 to $92, following a 30-day share price decline of 13.07% and a 25.4% decrease year-to-date. Despite reporting substantial revenues of $11.16 billion and 3.7% top-line growth, Abbott's consensus earnings estimate of $5.5 for the current fiscal year, coupled with a Zacks Rank #4 (Sell), indicates market concerns about its future performance. The company’s strong dividend history offers some reassurance, but investor caution persists as it nears its 52-week low.
“Abbott Laboratories (ABT.US)](https://www.fxstreet.cz/klicova-slova+abbott-laboratories-abtus.html)”
“Abbott · announced · new late-breaking data · strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios”
“Abbott · presented · late-breaking results · from a first-in-human clinical study evaluating Abbott's investigational AVEIR™ CSP leadless pacemaker system”
“Abbott Laboratories · presented · new multi-biomarker data · for Cancerguard multi cancer early detection test”
“Abbott Laboratories · has a · 30 day share price return · 13.07% decline”
“Abbott Laboratories · has a · 1 year total shareholder return · 27.83% decline”
“Abbott Laboratories · is a · compelling growth investment · with defensive qualities”
“Abbott Laboratories · trades at a · discount · to its estimated future cash flow value”
“Daiwa · downgraded · Abbott Laboratories · to Neutral from Outperform”
“Daiwa · lowered · price target on Abbott Laboratories · to $92 from $113”
“Matt Miksic · lowered · firm’s price recommendation on Abbott Laboratories · to $143 from $144”
“Abbott · has average brokerage recommendation · 1.57 · on a scale of 1 to 5”
